Who Exports Glimepiride from India — 242 Suppliers Behind a $76.3M Market
India's glimepiride export market is supplied by 242 active exporters who collectively shipped $76.3M across 3,159 shipments. INDOCO REMEDIES LIMITED leads with a 60.8% market share, followed by MICRO LABS LIMITED and IPCA LABORATORIES LIMITED. The top 5 suppliers together control 79.4% of total export value, reflecting a concentrated market structure.
Top Glimepiride Exporters from India — Ranked by Export Value
INDOCO REMEDIES LIMITED is the leading glimepiride exporter from India, holding a 60.8% share of the $76.3M market across 3,159 shipments from 242 exporters. The top 5 suppliers — INDOCO REMEDIES LIMITED, MICRO LABS LIMITED, IPCA LABORATORIES LIMITED, INVENTIA HEALTHCARE LIMITED, MEDREICH LIMITED — collectively control 79.4% of total export value, indicating a highly concentrated market. Individual shares are: INDOCO REMEDIES LIMITED (60.8%), MICRO LABS LIMITED (7.0%), IPCA LABORATORIES LIMITED (4.7%), INVENTIA HEALTHCARE LIMITED (3.9%), MEDREICH LIMITED (3.0%).
Top Glimepiride Exporters from India
Ranked by export value · 242 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | INDOCO REMEDIES LIMITED GLIMEPIRIDE TABLETS 4MG, PACK OF 500GLIMEPIRIDE TABLETS 2MG, PACK OF 500GLIMEPIRIDE TABLETS 1MG, PACKS OF 500 | $46.4M | 2 | 60.8% |
| 2 | MICRO LABS LIMITED GLIMEPIRIDE TABLETS 4MG, PACK OF 500GLIMEPIRIDE TABLETS 2MG, PACK OF 500GLIMEPIRIDE TABLETS 1MG, PACKS OF 500 | $5.3M | 18 | 7.0% |
| 3 | IPCA LABORATORIES LIMITED HARMLESS MEDICINES:GLIMEPIRIDE 4MG TABLETSGLIMEPIRIDE 1MG TABLETSHARMLESS MEDICINES:GLIMEPIRIDE 1MG TABLETS | $3.6M | 3 | 4.7% |
| 4 | INVENTIA HEALTHCARE LIMITED PERGLIM M-2TAB.GLUCOCARE TABLETS (GLIMEPIRIDE USP 1LUPIMET (GLIMEPIRIDE 2MG AND METFORMIN H | $3.0M | 6 | 3.9% |
| 5 | MEDREICH LIMITED GLIMEPIRIDE 1MG TABLETS PO NO.MM-158-22GLIMEPIRIDE 0.5MG TABLETS PO NO.MM-158-GLIMEPIRIDE 1MG TABLETS, PO NO.MM-152, P | $2.3M | 1 | 3.0% |
| 6 | SUN PHARMACEUTICAL INDUSTRIES LIMITED GEMER 2 TABLETS (GLIMEPIRIDE AND EXTENDEGEMER 2 TABLETS PACK BOX5X10SNOSGEMER 2 TABLETS PACK: BOX5X10SNOS | $1.6M | 4 | 2.0% |
| 7 | FREDUN PHARMACEUTICALS LTD GLIMEPIRIDE BP 1 MG TABLETPHARMACEUTICALS PRODUCTS:GLIMEPIRIDE BP4 MG TABLETSNOS | $1.4M | 1 | 1.8% |
| 8 | MYLAN LABORATORIES LIMITED HARMLESS MEDICINES GLIMEPIRIDE TAB 3MG90BL FR VIAGLIMEPIRIDE TAB 4MG 30BL FR VIA PACKS 33344 | $1.3M | 4 | 1.7% |
| 9 | AJANTA PHARMA LIMITED LUPIMET (GLIMEPIRIDE 2MG AND METFORMIN HLUPIMET GLIMEPIRIDE 2MG AND METFORMIN HGLIMEPIRIDE + METFORMIN HYDROC | $1.2M | 3 | 1.5% |
| 10 | AUROBINDO PHARMA LTD GLIMEPRIDE TABLETS 3MG(GLIMEPIRIDE AUROBGEMER 2 TABLETS (GLIMEPIRIDE AND EXTENDEGLIMEPRIDE TABLETS 2MG(GLIMEPIRIDE AUROB | $882.8K | 3 | 1.2% |
| 11 | DR REDDY S LABORATORIES LIMITED GLIMEPIRIDE TABLETS 4MG, PACK OF 500GLIMEPIRIDE TABLETS 2MG, PACK OF 500GLIMEPIRIDE TABLETS 1MG, PACKS OF 500 | $712.6K | 1 | 0.9% |
| 12 | DR REDDYS LABORATORIES LIMITED GLIMEPIRIDE TABLETS 4MG, PACK OF 500GLIMEPIRIDE TABLETS 2MG, PACK OF 500GLIMEPIRIDE TABLETS 1MG, PACKS OF 500 | $696.6K | 1 | 0.9% |
| 13 | ZENTIVA PRIVATE LIMITED | $693.1K | 1 | 0.9% |
| 14 | AZTEC PHARMA PRIVATE LIMITED LUPIMET (GLIMEPIRIDE 2MG AND METFORMIN HLUPIMET GLIMEPIRIDE 2MG AND METFORMIN HGLIMEPIRIDE + METFORMIN HYDROC | $607.9K | 1 | 0.8% |
| 15 | INTAS PHARMACEUTICALS LIMITED HARMLESS MEDICINES:GLIMEPIRIDE 4MG TABLETSGLIMEPIRIDE 1MG TABLETSHARMLESS MEDICINES:GLIMEPIRIDE 1MG TABLETS | $508.7K | 4 | 0.7% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Glimepiride exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| INDOCO REMEDIES LIMITED | Approved | Yes | Yes | 2 | Received final ANDA approval for Pregabalin capsules and tentative approval for |
| IPCA LABORATORIES LIMITED | Approved | Yes | Yes | 10 | Manufactures APIs and formulations; received FDA warning letter for Boisar facil |
| DR. REDDY'S LABORATORIES LIMITED | Approved | Yes | Yes | 15 | Global pharmaceutical company with multiple FDA approvals; received warning lett |
| INTAS PHARMACEUTICALS LIMITED | Approved | Yes | Yes | 8 | Received FDA warning letter for Sanand facility in December 2022 due to data fal |
| MICRO LABS LIMITED | Approved | Yes | Yes | 5 | Operates 14 GMP-compliant manufacturing plants in India, catering to regulated m |
| INVENTIA HEALTHCARE LIMITED | Approved | Yes | Yes | 2 | Listed in FDA's Approved Drug Products List for Metformin Hydrochloride. |
| AUROBINDO PHARMA LTD | Approved | Yes | Yes | 20 | Major exporter of generic pharmaceuticals with multiple FDA approvals. |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | Approved | Yes | Yes | 25 | Largest pharmaceutical company in India with extensive global presence. |
| MYLAN LABORATORIES LIMITED | Approved | Yes | Yes | 30 | Part of Viatris; significant portfolio of FDA-approved products. |
| AJANTA PHARMA LIMITED | Approved | Yes | Yes | 10 | Specializes in branded generics with a focus on emerging markets. |
TransData Nexus reviewed the regulatory standing of 10 leading Glimepiride exporters from India. 10 hold US FDA facility approvals, 10 maintain WHO-GMP certification, and 10 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Glimepiride sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for Active Pharmaceutical Ingredients (APIs) production. The city's pharmaceutical ecosystem is bolstered by a robust infrastructure, skilled workforce, and supportive government policies. While specific data on Glimepiride API production in Hyderabad is not detailed in the provided information, the city's prominence in API manufacturing suggests a significant role in the supply chain for such drugs.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This region hosts numerous manufacturing units specializing in the production of finished dosage forms, including tablets and capsules. Given the area's emphasis on formulations, it is likely that Glimepiride tablets are produced here, catering to both domestic and international markets.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for pharmaceutical products. Indoco Remedies Limited, headquartered in Mumbai, operates multiple manufacturing facilities, including those in Goa and Baddi, which have received approvals from regulatory authorities such as the USFDA and UK-MHRA. These facilities are instrumental in producing and exporting Glimepiride formulations, contributing significantly to the company's export figures.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh is a prominent pharmaceutical manufacturing zone, benefiting from tax incentives and a conducive business environment. Indoco Remedies Limited has a manufacturing facility in Baddi, approved by UK-MHRA and WHO-GMP, which likely contributes to the production of Glimepiride formulations.
5Sourcing Recommendations
- Diversify Supplier Base: While Indoco Remedies Limited is the leading exporter of Glimepiride, accounting for 60.8% of exports, it's prudent to engage with other suppliers such as Micro Labs Limited and IPCA Laboratories Limited to mitigate supply chain risks.
- Assess Manufacturing Capabilities: Evaluate the manufacturing facilities of potential suppliers, ensuring they have the necessary regulatory approvals (e.g., USFDA, UK-MHRA) and capacity to meet demand.
- Monitor Regulatory Compliance: Stay informed about any regulatory actions or inspections concerning suppliers. For instance, Indoco Remedies Limited received a warning letter from the USFDA in 2019 for its Goa Plant I facility, highlighting the importance of ongoing compliance monitoring.
- Consider Geographic Distribution: Engage suppliers from different pharmaceutical clusters (e.g., Hyderabad for APIs, Ahmedabad-Vadodara for formulations) to leverage regional strengths and ensure a resilient supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Glimepiride exporters from India
Indoco Remedies Limited — Indoco partners with Clarity Pharma to strengthen UK presence
Indoco Remedies Limited announced a strategic collaboration with Clarity Pharma, UK, to launch approximately 20 pharmaceutical products in the UK market over the next 18 months. This partnership aims to combine Indoco's portfolio of high-quality, affordable pharmaceutical products with Clarity Pharma's extensive distribution network and market expertise.
Impact: This collaboration is expected to enhance Indoco's market reach in the UK, potentially increasing demand for their products, including Glimepiride, thereby positively impacting export volumes.
Indoco Remedies Limited — Indoco acquires 85% stake in US-based FPP Holding Company
Indoco Remedies Limited acquired an 85% equity stake in FPP Holding Company, LLC, a US-based firm. This acquisition is part of Indoco's strategy to strengthen its presence in the US market and expand its product portfolio.
Impact: The acquisition is likely to bolster Indoco's export capabilities, including Glimepiride, by leveraging FPP Holding's established market presence in the US.
Ipca Laboratories Limited — Ipca Laboratories invests in Unichem
Ipca Laboratories Limited made a strategic investment in Unichem Laboratories, aiming to enhance its manufacturing capabilities and expand its product offerings. This move is part of Ipca's broader strategy to strengthen its position in the pharmaceutical industry.
Impact: The investment is expected to increase Ipca's production capacity, potentially leading to higher export volumes of products like Glimepiride.
Common Questions — Glimepiride Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which glimepiride supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, INDOCO REMEDIES LIMITED leads with 41 recorded shipments worth $46.4M. MICRO LABS LIMITED (439 shipments) and IPCA LABORATORIES LIMITED (90 shipments) are also established high-volume exporters.
Q How many glimepiride manufacturers are there in India?
India has 242 active glimepiride exporters with a combined export market of $76.3M across 3,159 shipments to 94 countries. The top 5 suppliers hold 79.4% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for glimepiride from India?
Average FOB unit price: $281.82 per unit, ranging from $0.00 to $35653.63. Average shipment value: $24.2K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 242 verified Indian exporters of Glimepiride ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,159 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 94 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,159 Verified Shipments
242 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists